Clinical Trial Update: IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating the IRX-2 regimen for cervical intraepithelial neoplasia grade 3 and vulvar intraepithelial neoplasia grade 3 was terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia
• Vulvar Intraepithelial Neoplasia

Drugs mentioned

• IRX-2

Snippet

Sponsor: University of Southern California | Conditions: Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion | Phase 2 | Status: TERMINATED | Results posted: 2025-04-13